Merck & Co. is in talks to acquire the cancer-focused biotech company Revolution Medicines Inc., according to a report in the Financial Times.
The article comes one day after the Wall Street Journal reported that AbbVie Inc. was near a deal to buy Revolution. AbbVie said that story was inaccurate.
Read More: AbbVie Says It’s Not in Talks to Buy Revolution Medicines
The FT reported, citing a person familiar, that the price tag being discussed was between $28 billion and $32 billion. This would make it one of the biggest pharmaceutical deals since Pfizer Inc. bought Seagen Inc. for ...
